Want to see IN:MEDICO full AI Analyst Report?

Medico Remedies Ltd. (MEDICO) Price & Analysis

0 Followers

MEDICO Stock Chart & Stats

₹50.16

₹4.58(8.10%)

At close: Jan 08 4:00 PM EST

₹50.16

₹4.58(8.10%)

Day’s Range― - ―

52-Week Range₹31.00 - ₹56.99

Previous CloseN/A

Volume2.72M

Average Volume (3M)12.74K

Market Cap

₹3.40B

Enterprise Value₹3.74B

Total Cash (Recent Filing)₹37.51M

Total Debt (Recent Filing)₹192.04M

Price to Earnings (P/E)25.4

Beta0.10

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.59

Shares Outstanding82,984,000

10 Day Avg. Volume20,955

30 Day Avg. Volume12,740

Financial Highlights & Ratios

PEG Ratio0.70

Price to Book (P/B)3.60

Price to Sales (P/S)1.32

P/FCF Ratio-78.06

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sustained Revenue GrowthConsistent top‑line expansion since FY2023, with acceleration to ~20% in FY2026, signals durable demand and successful commercial execution. Sustained revenue growth supports scale, reinvestment capacity and a multi‑quarter foundation for earnings expansion and product reach.

Healthy Capital BaseSteady equity compounding and materially improved leverage through FY2025 provide a solid capital base. A stronger balance sheet increases resilience to shocks, supports funded expansion, and gives management flexibility for strategic investments without immediately relying on external financing.

Improving ProfitabilityMaterial net income improvement and historically stable ROE (~16%) indicate efficient capital deployment and operational improvement. Durable profitability provides internal funding for growth, strengthens investor returns potential, and cushions the business through cyclicality over coming quarters.

Bears Say

Weak Cash ConversionCash generation weakened materially in FY2026: OCF fell sharply and FCF turned negative despite higher reported earnings. Persistently volatile cash conversion limits self‑funding, raises refinancing risk, and can force tradeoffs between capex, working capital and shareholder returns over the medium term.

Margin VolatilityMeaningful swings in gross and operating margins reduce predictability of profitability and undermine operating leverage. Margin volatility may reflect exposure to input costs, pricing pressure or mix shifts, complicating long‑range planning and potentially compressing long‑term return profiles.

Rising Borrowings In FY2026After multi‑year leverage improvement, debt increased again in FY2026. Higher borrowings amid weakening cash flow raise interest and refinancing risks and reduce balance sheet flexibility, potentially constraining strategic initiatives or increasing funding costs over the next several quarters.

Medico Remedies Ltd. News

Medico Remedies Announces 31st AGM Details

Medico Remedies Ltd. ( ($IN:MEDICO) ) has provided an update. Medico Remedies Limited has announced the completion of...

11M ago

MEDICO FAQ

What was Medico Remedies Ltd.’s price range in the past 12 months?

Medico Remedies Ltd. lowest stock price was ₹31.00 and its highest was ₹56.99 in the past 12 months.

What is Medico Remedies Ltd.’s market cap?

Medico Remedies Ltd.’s market cap is ₹3.40B.

When is Medico Remedies Ltd.’s upcoming earnings report date?

Medico Remedies Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 33 days.

How were Medico Remedies Ltd.’s earnings last quarter?

Medico Remedies Ltd. released its earnings results on May 21, 2026. The company reported ₹0.71 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.71.

Is Medico Remedies Ltd. overvalued?

According to Wall Street analysts Medico Remedies Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medico Remedies Ltd. pay dividends?

Medico Remedies Ltd. does not currently pay dividends.

What is Medico Remedies Ltd.’s EPS estimate?

Medico Remedies Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medico Remedies Ltd. have?

Medico Remedies Ltd. has 82,984,000 shares outstanding.

What happened to Medico Remedies Ltd.’s price movement after its last earnings report?

Medico Remedies Ltd. reported an EPS of ₹0.71 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.041%.

Which hedge fund is a major shareholder of Medico Remedies Ltd.?

Currently, no hedge funds are holding shares in IN:MEDICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medico Remedies Ltd.

Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. Its product portfolio includes general formulations, which consists of general tablets, capsules, and dry syrups; and beta lactum formulations, which comprises penicillin and cephalosporin range of formulations in tablets, capsules, and dry syrups. The company was founded on March 18, 1994 and is headquartered in Thane, India.